Erika P. Hamilton, MD, highlights initial findings from the ongoing phase 1b/2 LIO-1 trial in advanced metastatic tumors.
Erika P. Hamilton, MD, director of the Breast Cancer and Gynecologic Cancer Research Program and principal investigator at the Sarah Cannon Research Institute, highlights initial findings from the ongoing phase 1b/2 LIO-1 trial (NCT04042116) in advanced metastatic tumors.
In the phase 1b portion of the study, investigators wanted to determine the recommended dose of lucitanib in combination with nivolumab (Opdivo) in patients with advanced solid tumors.
Encouraging activity, including complete and partial responses, was demonstrated in 17 patients who received the combination, says Hamilton. Additionally, stable disease was reported in 10 patients.
Notably, these data were seen across several tumor types, including those that do not typically respond to immunotherapy, Hamilton explains. As such, lucitanib/nivolumab is now being further evaluated in the phase 2 portion of the trial.
In the phase 2 setting, patients with gynecologic cancers will start on a 6 mg dose of lucitanib once daily. As tolerated, patients will escalate to 8 mg once daily and 10 mg once daily and receive 480 mg of intravenous nivolumab every 28 days, Hamilton concludes.